60419-23-0

基本信息
(R)-(-)-1-(2-吡咯烷基甲基)吡咯烷
(2R)-2-(1-Pyrrolidinylmethyl)pyrrolidine
(R)-1-(Pyrrolidin-2-ylMethyl)pyrrolidine
1-[(2R)-2-Pyrrolidinylmethyl]pyrrolidine
(R)-2-(Pyrrolidin-1-ylmethyl)pyrrolidine
1-(((R)-pyrrolidin-2-yl)methyl)pyrrolidine
(R)-(-)-1-(2-PYRROLIDINYLMETHYL)PYRROLIDINE
Pyrrolidine, 1-[(2R)-2-pyrrolidinylmethyl]-
(R)-2-(Pyrrolidin-1-ylmethyl)pyrrolidine 2HCl
(R)-(-)-1-(2-Pyrrolidinylmethyl)pyrrolidine98%
物理化學(xué)性質(zhì)
制備方法
![Pyrrolidine, 1-[(2R)-2-pyrrolidinylcarbonyl]- (9CI)](/CAS/GIF/144243-45-8.gif)
144243-45-8

60419-23-0
以(+)-芐氧羰基-D-脯氨酸(1.5 g,6 mmol)為原料,在DMF(20 mL)中依次加入EDC(2.3 g,12 mmol)、HOBt(800 mg,6 mmol)、TEA(1.5 mL)和吡咯烷(853 mg,12 mmol),室溫攪拌反應(yīng)18小時。反應(yīng)完成后,用水和碳酸氫鈉稀釋反應(yīng)液,用二氯甲烷(3×20 mL)萃取。合并有機(jī)相,濃縮后經(jīng)硅膠柱層析純化,得到(R)-2-(吡咯烷-1-羰基)-吡咯烷-1-羧酸芐酯。將所得(R)-2-(吡咯烷-1-羰基)-吡咯烷-1-羧酸芐酯溶于甲醇中,加入Pd/C催化劑,室溫氫化20小時,反應(yīng)完成后過濾除去催化劑,濃縮濾液得到吡咯烷-1-基-(R)-吡咯烷-2-基-甲酮。在0℃下,將吡咯烷-1-基-(R)-吡咯烷-2-基-甲酮(1.2 g,7.1 mmol)溶于THF(10 mL)中,緩慢加入B2H6(10 mL,10 mmol)。將反應(yīng)混合物加熱至回流,反應(yīng)16小時。反應(yīng)完成后,用HCl酸化反應(yīng)液,濃縮去除溶劑。殘余物用2N NaOH調(diào)節(jié)pH至10,用含5%甲醇的二氯甲烷溶液萃取。合并有機(jī)相,濃縮后經(jīng)硅膠柱層析純化,得到目標(biāo)產(chǎn)物(R)-1-(2-吡咯烷基甲基)吡咯烷800 mg,收率73%。
參考文獻(xiàn):
[1] Journal of Medicinal Chemistry, 1992, vol. 35, # 23, p. 4334 - 4343
[2] Patent: WO2004/76412, 2004, A2. Location in patent: Page 98
[3] Patent: US2003/125370, 2003, A1
[4] Patent: WO2017/17630, 2017, A1. Location in patent: Page/Page column 50